Veklury is a recommended therapy for reducing disease progression in Covid-19 patients. Credit: Diverse Stock Photos / Flickr (Creative Commons).

The US Food and Drug Administration (FDA) has granted approval to Gilead Sciences’ supplemental new drug application (sNDA) for Veklury (remdesivir) to treat paediatric Covid-19 patients aged over 28 days.

The treatment is indicated for patients who are admitted to the hospital or have mild-to-moderate disease and are at increased disease progression risk, including hospitalisation or death. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A nucleotide analog of the company, Veklury is a recommended therapy for lowering disease progression in non-hospitalised Covid-19 patients who are at increased risk.

This approval comes after Veklury obtained sNDA approval for treating non-hospitalised adult and adolescent patients at increased risk of disease progression.

A three-day treatment course of Veklury is advised for paediatric patients in the non-hospital setting under the latest expanded indication. 

In hospitalised patients who do not need invasive mechanical ventilation and/or ECMO, the FDA has recommended a five-day regimen.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The approval is based on findings from the open-label, single-arm Phase II/III CARAVAN clinical trial of Veklury. 

Results from CARAVAN showed that Veklury was well-tolerated in hospitalised Covid-19 paediatric patients while an increased proportion of subjects demonstrated clinical improvement and recovery. 

Gilead Sciences chief medical officer Merdad Parsey said: “The expanded indication for Veklury for the treatment of children is a testament to the safety, tolerability and efficacy profile of this therapy, which has remained the foundational antiviral for Covid-19 treatment. 

“With the recent opening of our Gilead Pediatric Center of Excellence in Dublin, which is responsible for coordinating paediatric clinical trials for treatments for HIV, hepatitis B and Covid-19, we will continue our research to help address unmet treatment needs for children.”